Migraine Clinical Trial
— MIGinPOL2021Official title:
Migraine in Poland - a Web-based Cross-sectional Survey
Verified date | May 2022 |
Source | Swiat Zdrowia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
A survey of Polish respondents will aim to define migraine characteristics in Polish subjects. To achieve this, a structured questionnaire based mainly on American Migraine Prevalence and Prevention Study has been prepared to serve as a tool for data extraction. The obtained data should allow for defining disease parameters, burden and received treatments. Additionally questions regarding patients rhinological symptoms and COVID-19-related history were included.
Status | Completed |
Enrollment | 2800 |
Est. completion date | April 30, 2022 |
Est. primary completion date | April 30, 2022 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - consent to participate in the study Exclusion Criteria: - responses missing in questionnaire |
Country | Name | City | State |
---|---|---|---|
Poland | Marcin Straburzynski | Dzwierzuty | Warminsko-mazurskie |
Poland | Department of Neurology, Wroclaw Medical University | Wroclaw |
Lead Sponsor | Collaborator |
---|---|
Swiat Zdrowia | Wroclaw Medical University |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Headache phenotype | Classification of reported headache according to International Classification of Headache Disorders | in the preceding year | |
Primary | Migraine burden | Consequences of the disease measured by the Migraine Disability Assessment Test | in the preceding year | |
Secondary | Monthly headache days | Number of days per month | in the preceding month | |
Secondary | Monthly headache days | Number of days per year | in the preceding year | |
Secondary | Time from last headache professional consultation | Number of months | in the preceding 10 years | |
Secondary | Migraine diagnosed by headache professional | yes/no | in the preceding 10 years | |
Secondary | Age at diagnosis | years | from the onset of headache (time frame up to 99 years) | |
Secondary | Comoribidities | Disease according to International Classsification of Disease 10 | in the preceding year | |
Secondary | Type of previous headache professional consultation | Name of headache profession/speciality | in the preceding 10 years | |
Secondary | Number of consultations in the last year | Number 0-100 | in the last 12 months | |
Secondary | Number of consultations in the last year because of headaches | Number 0-100 | in the last 12 months | |
Secondary | Number of days spent in hospital in the last year because of headaches | Number 0-100 | in the last 12 months | |
Secondary | Acute treatment used | Name of abortive medication | in the preceding 10 years | |
Secondary | Preventive treatment used | Name of abortive medication | in the preceding 10 years | |
Secondary | Acute treatment frequency | Number of days per month | in the last 3 months | |
Secondary | Preventive treatment frequency | Number of months form the last dose | in the last 12 months | |
Secondary | Preventive treatment effectiveness | Likert scale | in the last 12 months | |
Secondary | Employment | Type of employment | in the last 12 months | |
Secondary | Time spent at work | Number of hours per week | in the last 12 months | |
Secondary | Work absence due to headache | Number of days per month | in the last month | |
Secondary | Presenteeism | Number of days per month | in the last month | |
Secondary | PHQ-9 Patient Health Questionnaire | Number | in the last 2 weeks | |
Secondary | Sinus headache | Number of days | in the last 3 months | |
Secondary | Sinonasal symptoms accompanying headache | Type of symptoms | in the last 12 months | |
Secondary | Sinonasal symptoms not associated with headache | Type of symptom | in the last 12 months | |
Secondary | COVID-19 association with headache | Likert scale | in the last 2 years | |
Secondary | COVID-19 vaccine association with headache | Likert scale | in the last year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |